The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1590
ISSUE1590
January 27, 2020
Drugs for ADHD
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for ADHD
January 27, 2020 (Issue: 1590)
Attention-deficit/hyperactivity disorder (ADHD) is a
chronic neurodevelopmental disorder that has been
diagnosed in up to 10% of school-age children in the
US and frequently persists into adulthood. A study in
a large Danish cohort found that...more
- HM Feldman and MI Reiff. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 2014; 370:838.
- ND Volkow and JM Swanson. Clinical practice: adult attention deficit-hyperactivity disorder. N Engl J Med 2013; 369:1935.
- S Dalsgaard et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015; 385:2190.
- SE McCabe et al. Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: a multi-cohort national study. J Am Acad Child Adolesc Psychiatry 2016; 55:479.
- Z Chang et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry 2014; 71:319.
- P Lichtenstein et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367:2006.
- E Chan et al. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA 2016; 315:1997.
- ML Wolraich et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2019; 144:e20192528.
- D Coghill et al. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry 2013; 13:237.
- QuilliChew ER – extended-release chewable methylphenidate tablets. Med Lett Drugs Ther 2016; 58:68.
- Cotempla XR-ODT – another long-acting methylphenidate for ADHD. Med Lett Drugs Ther 2017; 59:183.
- Quillivant XR – an extended-release oral suspension of methylphenidate. Med Lett Drugs Ther 2013; 55:10.
- Transdermal methylphenidate (Daytrana) for ADHD. Med Lett Drugs Ther 2006; 48:49.
- Jornay PM – evening-dosed methylphenidate for ADHD. Med Lett Drugs Ther 2019; 61:126.
- Two new amphetamines for ADHD. Med Lett Drugs Ther 2016; 58:80.
- A new amphetamine oral suspension (Adzenys ER) for ADHD. Med Lett Drugs Ther 2018; 60:e106.
- RH Weisler et al. Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled, forced-dose clinical study. CNS Drugs 2017; 31:685.
- M Brams et al. SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: results of a randomized, double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 2018; 28:19.
- Lisdexamfetamine dimesylate (Vyvanse) for ADHD. Med Lett Drugs Ther 2007; 49:58.
- D Elbe et al. Focus on lisdexamfetamine: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2010; 19:303.
- JH Newcorn et al. Randomized, double-blind, placebo-controlled acute comparator trials of lisdexamfetamine and extended-release methylphenidate in adolescents with attention-deficit/hyperactivity disorder. CNS Drugs 2017; 31:999.
- SC Cohen et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2015; 54:728.
- JM Swanson et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 2017; 58:663.
- LV Moran et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019; 380:1128.
- L Hennissen et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs 2017; 31:199.
- WO Cooper et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365:1896.
- LA Habel et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306:2673.
- H Schelleman et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127:1102.
- SA Shahani et al. Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective. Pediatr Cardiol 2014; 35:485.
- LS Eiland et al. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. Ann Pharmcother 2014; 48:1350.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019; November 6 (epub). Available at medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- ST Osland et al. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2018, 6:CD007990.
- Guanfacine extended-release (Intuniv) for ADHD. Med Lett Drugs Ther 2010; 52:82.
- Another extended-release alpha2-agonist for ADHD. Med Lett Drugs Ther 2011; 53:10.
- Atomoxetine (Strattera) for ADHD. Med Lett Drugs Ther 2003; 45:11.
- JH Newcorn et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165:721.
- T Treuer et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol 2013; 23:179.
- VA Reed et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs 2016; 30:603.
- KF Huybrechts et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2018; 75:167.
- C Andrade. Risk of major congenital malformations associated with the use of methylphenidate or amphetamines in pregnancy. J Clin Psychiatry 2018; 79(1):18f12108.
- JM Cohen et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol 2017; 130:1192.
- C Andrade. Adverse gestational outcomes associated with attention-deficit/hyperactivity disorder medication exposure during pregnancy. J Clin Psychiatry 2018; 79(1):18f12136.
- S Cortese et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psycyiatry 2018; 5:727.
- JJ McGough et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2019; 58:403.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for ADHD
Article code: 1590a
Article code: 1590a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.